Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients

Roberto Fogari, Paola Preti, Annalisa Zoppi, Amedeo Mugellini, Luca Corradi, Pierangelo Lazzari, Tara Santoro, Giuseppe Derosa

Research output: Contribution to journalArticle


Objective: The aim of the study was to evaluate the effect of valsartan/ amlodipine combination on insulin sensitivity in overweight-obese hypertensive patients. Methods: After a 4-week placebo period, 58 overweight-obese (BMI ≥25 kg/m2) patients, with mild to moderate essential hypertension (DBP >95 and 140 mmHg) were treated with amlodipine 5 mg od or valsartan 160 mg od or amlodipine 5 mg plus valsartan 160 mg od for 8 weeks according to a randomized, open-label, blinded end-point, cross-over study. At the end of the placebo period and each treatment period, blood pressure (BP) and insulin sensitivity (IS) (by euglycemic hyperinsulinemic clamp technique) were evaluated. IS was expressed as the amount of glucose infused during the last 30 min (glucose infusion rate, GIR) in mg/kg/min. Results: Valsartan/amlodipine combination produced a significantly greater decrease in SBP/DBP values (-22.3/16.7 mmHg, p

Original languageEnglish
Pages (from-to)1851-1857
Number of pages7
JournalInternal Medicine
Issue number21
Publication statusPublished - 2008



  • Amlodipine
  • Hypertension
  • Insulin-sensitivity
  • Obesity
  • Overweight
  • Valsartan

ASJC Scopus subject areas

  • Internal Medicine

Cite this